Pherecydes Pharma
ALPHE | PA
Overview
Corporate Details
- ISIN(s):
- FR0011651694
- LEI:
- 894500LYT3UUN58X3I68
- Country:
- France
- Address:
- 22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of the most promising approach to fight these AMR infections. Pherecydes Pharma has introduced the concept of precision phagotherapy, which consists in treating each patient according to the activity of the phages on the bacterial strain responsible for the infection. Treatments are therefore individualized and adapted to each case.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-06-23 20:45 |
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
|
French | 214.3 KB | |
| 2023-06-23 20:45 |
Regulatory News Service
Inside Information / Other news releases
|
English | 213.8 KB | |
| 2023-06-14 20:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 197.1 KB | |
| 2023-06-14 20:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 200.6 KB | |
| 2023-06-08 07:30 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 297.3 KB | |
| 2023-06-08 07:30 |
Inside Information Statement
Inside Information / Other news releases
|
English | 269.4 KB | |
| 2023-06-05 08:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 198.4 KB | |
| 2023-06-05 08:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 192.1 KB | |
| 2023-06-02 20:00 |
General Meeting Notice
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 152.4 KB | |
| 2023-05-23 23:43 |
Regulatory News Service
News releases during takeover bids / Takeover bids Other news releases
|
English | 191.8 KB | |
| 2023-05-23 23:43 |
Regulatory News Service
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
|
French | 184.9 KB | |
| 2023-05-16 07:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 224.2 KB | |
| 2023-05-16 07:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 216.3 KB | |
| 2023-05-11 18:00 |
Regulatory News Service
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 200.6 KB | |
| 2023-04-27 18:00 |
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 195.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |